Clonal evolution and blast crisis correlate with enhanced proteolytic activity of Separase in BCR-ABL b3a2 fusion type CML under imatinib therapy

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Haaß, Wiltrud ^a   Kleiner, Helga ^a   Weiß, Christel ^a   Haferlach, Claudia ^b   Schlegelberger, Brigitte ^c   Müller, Martin C ^a   Hehlmann, Rüdiger ^a   Hofmann, Wolf Karsten ^a   Fabarius, Alice ^a   Seifarth, Wolfgang ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; IMATINIB; INTERFERON; SEPARASE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BCR ABL GENE; BLAST CELL CRISIS; CANCER COMBINATION CHEMOTHERAPY; CHROMOSOME BREAKAGE; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; DRUG DOSE COMPARISON; ENZYME ACTIVITY; FEEDBACK SYSTEM; FEMALE; GENE; GENE FUSION; HUMAN; HUMAN CELL; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA INTERFERENCE; CHROMOSOME ABERRATION; ENZYMOLOGY; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLAST CRISIS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOME BREAKAGE; CLONAL EVOLUTION; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PROTEOLYSIS; SEPARASE; YOUNG ADULT;

EID: 84939143043     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129648     Document Type: Article

References (55)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340. PMID: 10219069
2. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010-4022. PMID: 14982876
3. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European Leukemia-Net recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872-884. doi: 10.1182/blood-2013-05-501569 PMID: 23803709
4. Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A. Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood. 2012;119:530-539. doi: 10.1182/blood-2010-08-303495 PMID: 22101898
5. Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120:2254-2264. doi: 10.1172/JCI41246 PMID: 20592475
6. O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100:1628-1633. PMID: 12176881
7. Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, et al. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood. 2013;121:4175-4183. doi: 10.1182/blood-2012-11-466938 PMID: 23543457
8. Rosenhahn J, Weise A, Michel S, Hennig K, Hartmann I, Schiefner J, et al. Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R. Int J Oncol. 2007;31:121-128. PMID: 17549412
9. Schnittger S, Bacher U, Dicker F, Kern W, Alpermann T, Haferlach T, et al. Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. Genes Chromosomes Cancer. 2010;49:910-918. doi: 10.1002/gcc.20801 PMID: 20607847
10. Mitelman F, Levan G, Nilsson PG, Brandt L. Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer. 1976;18:24-30. PMID: 1065618
11. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:671-684. PMID: 15271399
12. Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118:6760-6768. doi: 10.1182/blood-2011-08-373902 PMID: 22039253
13. O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood. 2004;103:451-455. PMID: 14512312
14. Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia. 2003;17:461-463. PMID: 12592348
15. Baccarani M, Dreyling M. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl. 2009;4:105-107.
16. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature. 2009;460:278-282. doi: 10.1038/nature08136 PMID: 19506557
17. Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R, et al. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia. 2005;19:1192-1197. PMID: 15858613
18. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A. 2002;99:1978-1983. PMID: 11830638
19. Chan JY. A clinical overview of centrosome amplification in human cancers. Int J Biol Sci. 2011;7:1122-1144. PMID: 22043171
20. Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 2003;63:1398-1404. PMID: 12649205
21. Gao C, Furge K, Koeman J, Dykema K, Su Y, Cutler ML, et al. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci U S A. 2007;104:8995-9000. PMID: 17517657
22. Holland AJ, Cleveland DW. Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep. 2012;13:501-514. doi: 10.1038/embor.2012.55 PMID: 22565320
23. Giehl M, Fabarius A, Frank O, Erben P, Zheng C, Hafner M, et al. Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells. Leukemia. 2007;21:1971-1976. PMID: 17597804
24. Patel H, Gordon MY. Abnormal centrosome-centriole cycle in chronic myeloid leukaemia? Br J Haematol. 2009;146:408-417. doi: 10.1111/j.1365-2141.2009.07772.x PMID: 19563513
25. Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W, Schoch C, et al. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet. 2005;157:53-61. PMID: 15676148
26. Fabarius A, Giehl M, Frank O, Duesberg P, Hochhaus A, Hehlmann R, et al. Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia. 2005;19:1573-1578. PMID: 15990860
27. Fabarius A, Giehl M, Rebacz B, Kramer A, Frank O, Haferlach C, et al. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica. 2008;93:1145-1154. doi: 10.3324/haematol.12793 PMID: 18519516
28. Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphiapositive chronic myeloid leukemia. Leukemia. 2004;18:1340-1346. PMID: 15190256
29. Giehl M, Leitner A, Haferlach C, Duesberg P, Hofmann WK, Hofheinz R, et al. Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors. Eur J Haematol. 2010;85:139-148. doi: 10.1111/j.1600-0609.2010.01459.x PMID: 20408871
30. Nigg EA. Centrosome duplication: of rules and licenses. Trends Cell Biol. 2007;17:215-221. PMID: 17383880
31. Schockel L, Mockel M, Mayer B, Boos D, Stemmann O. Cleavage of cohesin rings coordinates the separation of centrioles and chromatids. Nat Cell Biol. 2011;13:966-972. doi: 10.1038/ncb2280 PMID: 21743463
32. Simmons-Kovacs LA, Haase SB. Cohesin: it's not just for chromosomes anymore. Cell Cycle. 2010;9:1750-1753. PMID: 20436287
33. Nakamura A, Arai H, Fujita N. Centrosomal Aki1 and cohesin function in separase-regulated centriole disengagement. J Cell Biol. 2009;187:607-614. doi: 10.1083/jcb.200906019 PMID: 19948489
34. Tsou MF, Wang WJ, George KA, Uryu K, Stearns T, Jallepalli PV. Polo kinase and separase regulate the mitotic licensing of centriole duplication in human cells. Dev Cell. 2009;17:344-354. doi: 10.1016/j. devcel.2009.07.015 PMID: 19758559
35. Meyer R, Fofanov V, Panigrahi A, Merchant F, Zhang N, Pati D. Overexpression and mislocalization of the chromosomal segregation protein separase in multiple human cancers. Clin Cancer Res. 2009;15:2703-2710. doi: 10.1158/1078-0432. CCR-08-2454 PMID: 19351757
36. Mukherjee M, Ge G, Zhang N, Edwards DG, Sumazin P, Sharan SK, et al. MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas. Oncogene. 2014;33:5511-5522. doi: 10.1038/onc.2013.493 PMID: 24276237
37. Mukherjee M, Byrd T, Brawley VS, Bielamowicz K, Li XN, Merchant F, et al. Overexpression and constitutive nuclear localization of cohesin protease Separase protein correlates with high incidence of relapse and reduced overall survival in glioblastoma multiforme. J Neurooncol. 2014;119:27-35. doi: 10. 1007/s11060-014-1458-6 PMID: 24792645
38. Chestukhin A, Pfeffer C, Milligan S, DeCaprio JA, Pellman D. Processing, localization, and requirement of human separase for normal anaphase progression. Proc Natl Acad Sci U S A. 2003;100:4574-4579. PMID: 12672959
39. Hellmuth S, Bottger F, Pan C, Mann M, Stemmann O. PP2A delays APC/C-dependent degradation of separase-associated but not free securin. EMBO J. 2014;33:1134-1147. doi: 10.1002/embj. 201488098 PMID: 24781523
40. Holland AJ, Taylor SS. Cyclin-B1-mediated inhibition of excess separase is required for timely chromosome disjunction. J Cell Sci. 2006;119:3325-3336. PMID: 16868023
41. Waizenegger I, Gimenez-Abian JF, Wernic D, Peters JM. Regulation of human separase by securin binding and autocleavage. Curr Biol. 2002;12:1368-1378. PMID: 12194817
42. Haass W, Stehle M, Nittka S, Giehl M, Schrotz-King P, Fabarius A, et al. The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib. PLoS One. 2012;7:e42863. doi: 10. 1371/journal.pone.0042863 PMID: 22870341
43. Rossi MR, Masters JR, Park S, Todd JH, Garrett SH, Sens MA, et al. The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect. 2001;109:801-808. PMID: 11564615
44. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods. 2001;25:402-408. PMID: 11846609
45. Basu D, Zhang N, Panigrahi AK, Horton TM, Pati D. Development and validation of a fluorogenic assay to measure separase enzyme activity. Anal Biochem. 2009;392:133-138. doi: 10.1016/j.ab.2009.05. 046 PMID: 19497291
46. Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005;65:8912-8919. PMID: 16204063
47. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653. PMID: 15618470
48. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet. 2011;50:551-603. doi: 10.2165/11593320-000000000-00000 PMID: 21827214
49. Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415-423. doi: 10.1200/JCO.2013.49.9020 PMID: 24297946
50. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer. 2000;36:1395-1401. PMID: 10899653
51. Nicholson JM, Cimini D. Cancer karyotypes: survival of the fittest. Front Oncol. 2013;7:148.
52. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767-1773. PMID: 16855631
53. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer. 2010;116:2673-2681. doi: 10.1002/cncr.25015 PMID: 20499401
54. Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014;99:1441-1447. doi: 10.3324/haematol.2013.096537 PMID: 24837466
55. Zhang N, Scorsone K, Ge G, Kaffes CC, Dobrolecki LE, Mukherjee M, et al. Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy. J Biomol Screen. 2014;19:878-889. PMID: 24525869